205 related articles for article (PubMed ID: 32066862)
1. Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes.
Ru Y; Zhang X; Song T; Ding Y; Zhu Z; Fan Y; Xu Y; Sun A; Qiu H; Jin Z; Tang X; Han Y; Fu Z; Chen S; Ma X; Chen F; Chen J; Wu D
Bone Marrow Transplant; 2020 Sep; 55(9):1754-1762. PubMed ID: 32066862
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
3. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
4. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
5. Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello A; Piñana JL; Bataller L; Montoro J; Romero S; Navarro I; Lorenzo I; Andreu R; Guerreiro M; Aguilar C; Gorriz D; Dominguez L; de la Puerta R; Gómez I; Solves P; Jarque I; Sanz MÁ; Sanz G; Sanz J
Transplant Cell Ther; 2021 Mar; 27(3):261.e1-261.e7. PubMed ID: 33781531
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
Lindsay J; Othman J; Yong MK; Ritchie D; Chee L; Tay K; Tio SY; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Greenwood M; Pergam SA; Liu C; Slavin MA
Transpl Infect Dis; 2021 Oct; 23(5):e13719. PubMed ID: 34453768
[TBL] [Abstract][Full Text] [Related]
7. Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus.
Han SB; Bae EY; Lee JW; Jang PS; Lee DG; Chung NG; Jeong DC; Cho B; Lee SJ; Kang JH; Kim HK
Int J Hematol; 2014 Aug; 100(2):188-99. PubMed ID: 24981711
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
van Esser JW; van der Holt B; Meijer E; Niesters HG; Trenschel R; Thijsen SF; van Loon AM; Frassoni F; Bacigalupo A; Schaefer UW; Osterhaus AD; Gratama JW; Löwenberg B; Verdonck LF; Cornelissen JJ
Blood; 2001 Aug; 98(4):972-8. PubMed ID: 11493441
[TBL] [Abstract][Full Text] [Related]
9. Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation.
Marjanska A; Styczynski J
Expert Opin Biol Ther; 2023; 23(6):539-552. PubMed ID: 36971380
[TBL] [Abstract][Full Text] [Related]
10. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
Niu YY; Dong YJ; Yin Y; Xu WL; Liang ZY; Wang Q; Li Y; Liu W; Ou JP; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):904-910. PubMed ID: 35045651
[No Abstract] [Full Text] [Related]
11. Features of Epstein-Barr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen.
Ru Y; Zhu J; Song T; Ding Y; Zhu Z; Fan Y; Xu Y; Sun A; Qiu H; Jin Z; Tang X; Han Y; Fu C; Chen S; Ma X; Chen F; Chen J; Wu D
Front Cell Infect Microbiol; 2022; 12():865170. PubMed ID: 35651756
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and outcomes of Epstein-Barr virus viral load after allogeneic hematopoietic stem cell transplantation.
Tsushima T; Masuda SI; Yoda N; Kainuma S; Kimeda C; Konno S; Tanaka K; Matsuo K; Shimoji S; Kimura K; Arai H; Utsu Y; Imadome KI; Aotsuka N
Ann Hematol; 2024 Mar; 103(3):935-946. PubMed ID: 38157001
[TBL] [Abstract][Full Text] [Related]
13. Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes.
Stocker N; Labopin M; Boussen I; Paccoud O; Bonnin A; Malard F; Amiel C; Gozlan J; Battipaglia G; Duléry R; Giannotti F; Ruggeri A; Gaugler B; Mohty M; Brissot E
Bone Marrow Transplant; 2020 Mar; 55(3):586-594. PubMed ID: 31562397
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation.
Liu L; Zhang X; Feng S
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1341-1349. PubMed ID: 29530767
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
van Esser JW; Niesters HG; van der Holt B; Meijer E; Osterhaus AD; Gratama JW; Verdonck LF; Löwenberg B; Cornelissen JJ
Blood; 2002 Jun; 99(12):4364-9. PubMed ID: 12036863
[TBL] [Abstract][Full Text] [Related]
17. Incidence, risk factors, and clinical significance of Epstein-Barr virus reactivation in myelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation.
Wang H; Zhang TT; Qi JQ; Chu TT; Miao M; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
Ann Hematol; 2019 Apr; 98(4):987-996. PubMed ID: 30715567
[TBL] [Abstract][Full Text] [Related]
18. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
[TBL] [Abstract][Full Text] [Related]
19. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
20. [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
Han TT; Xu LP; Liu DH; Liu KY; Zhang XH; Chen H; Chen YH; Han W; Wang FR; Wang Y; Wang JZ; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):651-4. PubMed ID: 23978013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]